QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Biosimilars and Generics—Regulatory and Pharmacovigilance Differences

Test your understanding of the concepts covered by Biosimilars and Generics: Regulatory and Pharmacovigilance Differences.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement about conventional generics is most consistent with the article?

Bioequivalence is required in exactly the same form for every generic product Generics contain biological active substances that require comparative immunogenicity assessment Bioequivalence may be an appropriate bridge when systemic exposure is a suitable surrogate, but product-specific evidence requirements can differ Generics are outside the EU pharmacovigilance framework once authorised

Question 2 of 10 What is the principal purpose of preserving detailed exposure chronology in a pharmacovigilance database?

To establish causality automatically from the order of administration To enable assessment of initiation, duration, interruption and switching in relation to the clinical event To determine which product is legally equivalent to the reference product To replace the need for clinical evaluation of the reported event

Question 3 of 10 Which of the following represents a governance failure identified by the article?

Using reference-product knowledge as one element of a documented assessment Selecting product-level or active-substance-level analysis according to the scientific question Pooling related products before determining whether product-level analysis is necessary Documenting uncertainty and the rationale for the pharmacovigilance conclusion

Question 4 of 10 A spontaneous report concerns an adverse event after administration of a biosimilar. The case processor records only the shared active substance and assigns the exposure to the reference biological product. What is the principal problem?

The case should have been excluded because biosimilars cannot generate valid spontaneous reports The product identity and attribution of exposure have been lost Reference-product information must never be used in biosimilar assessment The case should automatically be classified as a manufacturing defect

Question 5 of 10 A safety communication concerns a risk established for a biological mechanism but supported by stronger evidence for some products than others. How should the communication be framed?

State that every biological product has the same demonstrated level of risk Limit the communication to the single product with the largest number of reports, regardless of evidence Describe the concern at the level supported by evidence and distinguish shared mechanism information from product-specific evidence Avoid mentioning the risk until identical evidence exists for every product

Question 6 of 10 A company is designing training for case processors handling both generics and biosimilars. Which training objective is most consistent with the article?

Teach staff to treat all products sharing an active substance as one exposure category Teach staff that biosimilars require a separate end-to-end pharmacovigilance system Teach staff to preserve product identity, reconstruct relevant exposure history and understand the equivalence-versus-biosimilarity distinction Teach staff to assume that a reference-product event applies identically to all alternatives

Question 7 of 10 Which statement best captures the article's distinction between the product exposed and the evidence used to interpret exposure?

Reference-product evidence changes the identity of a biosimilar exposure The product administered must remain correctly identified even when reference-product knowledge informs interpretation Only the active substance is relevant for case attribution; product identity is interpretive context A biosimilar report should be reassigned to the reference product when the event is already known

Question 8 of 10 Which statement best explains why immunogenicity receives particular attention for many biosimilars?

Therapeutic proteins can induce immune responses influenced by molecular characteristics, aggregation, impurities, formulation, route and patient factors Biosimilars are deliberately designed to be more immunogenic than reference products Generics cannot cause hypersensitivity reactions Immunogenicity is the only safety issue relevant to biological medicines

Question 9 of 10 An event has not previously been established for the reference biological medicine but is reported for a biosimilar. What is the appropriate interpretation?

It is automatically a biosimilar-specific signal It is automatically unrelated to the biosimilar because the reference product has no such risk It requires evaluation of evidence strength, consistency, exposure, alternative explanations and biological plausibility It should be attributed to the reference product because the products are comparable

Question 10 of 10 Which statement best describes the role of the reference product in biosimilar development?

It is used only to establish the product name after authorisation It is a benchmark for analytical and functional comparison and provides established clinical and safety context It is replaced by an active-substance database once clinical trials begin It determines that every safety event observed with the biosimilar is caused by the reference product

Knowledge Assessment: Biosimilars and Generics—Regulatory and Pharmacovigilance Differences

Cookie Settings